Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general meeting of shareholders held on May 13, 2022 (the "Meeting"). A total of 42,387,564 common shares, representing approximately 34.31% of the Company's issued and outstanding shares were represented at the meeting.
The following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
Votes For | Votes Withheld | |||
Director | # | % | # | % |
Dr. Peter Seufer-Wasserthal | 36,177,987 | 99.18% | 300,231 | 0.82% |
Trevor Peters | 36,166,230 | 99.14% | 311,988 | 0.86% |
Dr. Fotis Kalantzis | 35,666,513 | 97.77% | 811,705 | 2.23% |
Donald Archibald | 36,092,217 | 98.94% | 386,001 | 1.06% |
Sadiq H. Lalani | 35,671,203 | 97.79% | 807,015 | 2.21% |
Al Foreman | 35,867,631 | 98.33% | 610,587 | 1.67% |
Barbara Munroe | 36,160,678 | 99.13% | 317,540 | 0.87% |
In addition, shareholders approved the appointment of KPMG LLP as the Company's auditor for the ensuing year (99.99% of the votes cast being in favour). For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated May 13, 2022 available on SEDAR at www.sedar.com.
Willow is a leading biotechnology company that develops and produces high-purity, plant derived ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow's FutureGrown™ biotechnology platform allows large-scale production of pure, consistent, and sustainable products to benefit our B2B partners and their customers.
| Last Trade: | US$0.003 |
| Daily Change: | -0.0031 -50.82 |
| Daily Volume: | 300 |
| Market Cap: | US$433K |
March 14, 2025 November 12, 2024 November 07, 2024 September 18, 2024 September 05, 2024 | |
